The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia
作者:Ginny D. Ho、W. Michael Seganish、Ana Bercovici、Deen Tulshian、William J. Greenlee、Rachel Van Rijn、Alan Hruza、Li Xiao、Diane Rindgen、Deborra Mullins、Mario Guzzi、Xiaoping Zhang、Carina Bleickardt、Robert Hodgson
DOI:10.1016/j.bmcl.2012.01.113
日期:2012.4
The identification of potent and orally active dihydroimidazoisoquinolines as PDE 10A inhibitors is reported. The SAR development led to the discovery of compound 35 as a potent, selective, and orally active PDE10A inhibitor. Compound 35 inhibited MK-801-induced hyperactivity at 3 mg/kg and displayed a 10-fold separation between the minimal effective doses for inhibition of MK-801-induced hyperactivity and hypolocomotion in rats. (C) 2012 Elsevier Ltd. All rights reserved.